Lineage Cell Therapeutics, Inc. (AMEX: LCTX) is a Healthcare company (Biotechnology) with a market capitalization of $206M. The Maz Rating grades it against the other companies in its sector.
Lineage Cell Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.82, Lineage Cell Therapeutics, Inc. trades at 124.6x trailing earnings, 18.9x sales and 3.1x book value. Over the last twelve months it generated about $11M of revenue and $2M of net income. It runs a gross margin of 95.9%, an operating margin of -280.3% and a net margin of 16.2%. It shows return on equity of 3.1%, return on invested capital of 21.0% and a free cash flow yield of -12.8%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 5.96. Over the past 52 weeks the share price ranged from $0.77 to $1.99, with a beta of 1.69.
Lineage Cell Therapeutics, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 5 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.